Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia (CML), but the frequency of resistance increases in advancing stages of disease. Elimination of BCR/ABL-dependent intracellular signals triggers apoptosis, but it is unclear whether this activates additional cell survival and/or death pathways. We have shown here that IM induces autophagy in CML blast crisis cell lines, CML primary cells, and p210BCR/ABL-expressing myeloid precursor cells. IM-induced autophagy did not involve c-Abl or Bcl-2 activity but was associated with ER stress and was suppressed by depletion of intracellular Ca2+, suggesting it is mechanistically nonoverlapping with IM-induced apoptosis. We further demonstrated that suppression of autophagy using either pharmacological inhibitors or RNA interference of essential autophagy genes enhanced cell death induced by IM in cell lines and primary CML cells. Critically, the combination of a tyrosine kinase inhibitor (TKI), i.e., IM, nilotinib, or dasatinib, with inhibitors of autophagy resulted in near complete elimination of phenotypically and functionally defined CML stem cells. Together, these findings suggest that autophagy inhibitors may enhance the therapeutic effects of TKIs in the treatment of CML.

Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells / Bellodi, C; Lidonnici, Mr; Hamilton, A; Helgason, Gv; Soliera, Angela Rachele; Ronchetti, M; Galavotti, Sara; Young, Kw; Selmi, Tommaso; Yacobi, R; Van Etten, Ra; Donato, N; Hunter, A; Dinsdale, D; Tirrò, E; Vigneri, P; Nicotera, P; Dyer, Mj; Holyoake, T; Salomoni, P; Calabretta, Bruno. - In: THE JOURNAL OF CLINICAL INVESTIGATION. - ISSN 0021-9738. - STAMPA. - 119:5(2009), pp. 1109-1123. [10.1172/JCI35660]

Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells

SOLIERA, Angela Rachele;GALAVOTTI, SARA;SELMI, TOMMASO;CALABRETTA, Bruno
2009

Abstract

Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia (CML), but the frequency of resistance increases in advancing stages of disease. Elimination of BCR/ABL-dependent intracellular signals triggers apoptosis, but it is unclear whether this activates additional cell survival and/or death pathways. We have shown here that IM induces autophagy in CML blast crisis cell lines, CML primary cells, and p210BCR/ABL-expressing myeloid precursor cells. IM-induced autophagy did not involve c-Abl or Bcl-2 activity but was associated with ER stress and was suppressed by depletion of intracellular Ca2+, suggesting it is mechanistically nonoverlapping with IM-induced apoptosis. We further demonstrated that suppression of autophagy using either pharmacological inhibitors or RNA interference of essential autophagy genes enhanced cell death induced by IM in cell lines and primary CML cells. Critically, the combination of a tyrosine kinase inhibitor (TKI), i.e., IM, nilotinib, or dasatinib, with inhibitors of autophagy resulted in near complete elimination of phenotypically and functionally defined CML stem cells. Together, these findings suggest that autophagy inhibitors may enhance the therapeutic effects of TKIs in the treatment of CML.
2009
119
5
1109
1123
Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells / Bellodi, C; Lidonnici, Mr; Hamilton, A; Helgason, Gv; Soliera, Angela Rachele; Ronchetti, M; Galavotti, Sara; Young, Kw; Selmi, Tommaso; Yacobi, R; Van Etten, Ra; Donato, N; Hunter, A; Dinsdale, D; Tirrò, E; Vigneri, P; Nicotera, P; Dyer, Mj; Holyoake, T; Salomoni, P; Calabretta, Bruno. - In: THE JOURNAL OF CLINICAL INVESTIGATION. - ISSN 0021-9738. - STAMPA. - 119:5(2009), pp. 1109-1123. [10.1172/JCI35660]
Bellodi, C; Lidonnici, Mr; Hamilton, A; Helgason, Gv; Soliera, Angela Rachele; Ronchetti, M; Galavotti, Sara; Young, Kw; Selmi, Tommaso; Yacobi, R; Van Etten, Ra; Donato, N; Hunter, A; Dinsdale, D; Tirrò, E; Vigneri, P; Nicotera, P; Dyer, Mj; Holyoake, T; Salomoni, P; Calabretta, Bruno
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/640998
Citazioni
  • ???jsp.display-item.citation.pmc??? 244
  • Scopus 489
  • ???jsp.display-item.citation.isi??? 460
social impact